1. Pascal KE, Dudgeon D, Trefry JC, et al. Development of clinical-stage human monoclonal antibodies that treat advanced Ebola virus disease in nonhuman primates. J Infect Dis. 2018;218(Suppl 5):S612–26.
2. US Food & Drugs Administration. FDA approves first treatment for ebola virus [media release]. 14 Oct 2020. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-ebola-virus.
3. Regeneron Pharmaceuticals. INMAZEB™ (atoltivimab, maftivimab, and odesivimab-ebgn) injection, for intravenous use: US prescribing information. 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761169s000lbl.pdf. Accessed 6 Nov 2020.
4. Regeneron Pharmaceuticals. Regeneron announces agreement with BARDA for the development of new antibody treatment for Ebola [media release]. 21 Sep 2015. http://www.regeneron.com.
5. Regeneron Pharmaceuticals. Regeneron announces new collaborations with HHS to develop antibodies against Ebola, influenza and multiple other emerging pathogens [media release]. 2 Oct 2017. http://www.regeneron.com.